Table 3.
Univariate and multivariate analyses of clinicopathologic factors and SII for OS of patients with gastric cancer
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex | 0.904 (0.707–1.155) | 0.420 | NI | |
| Age | 1.301 (1.027–1.647) | 0.029 | 1.356 (1.059–1.735) | 0.026 |
| Tumor location | 0.766 (0.672–0.873) | <0.001 | 0.874 (0.762–1.003) | 0.056 |
| Tumor size | 2.421 (1.897–3.092) | <0.001 | 1.290 (0.997–1.670) | 0.017 |
| Pathologic type | 0.984 (0.886–1.092) | 0.758 | NI | |
| Borrmann classification | 1.790 (1.524–2.103) | <0.001 | 1.521 (1.279–1.810) | <0.001 |
| TNM stage | 2.428 (2.087–2.825) | <0.001 | 2.081 (1.772–2.443) | <0.001 |
| CEA | 1.844 (1.303–2.609) | 0.001 | 1.431 (1.006–2.035) | 0.027 |
| NLR | 1.581 (1.250–2.001) | <0.001 | 0.902 (0.637–1.278) | 0.563 |
| PLR | 1.738 (1.332–2.267) | <0.001 | 1.272 (0.902–1.794) | 0.170 |
| SII | 1.848 (1.455–2.348) | <0.001 | 1.551 (1.211–1.987) | 0.015 |
HR, hazard ratio; NI, not included; OS, overall survival; CI, confidence interval; CEA, carcinoembryonic antigen; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune-inflammation index